These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 18458892)

  • 1. CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels.
    Josephson F; Bertilsson L; Böttiger Y; Flamholc L; Gisslén M; Ormaasen V; Sönnerborg A; Diczfalusy U
    Eur J Clin Pharmacol; 2008 Aug; 64(8):775-81. PubMed ID: 18458892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of ritonavir, atazanavir and their combination on the CYP3A4 induction potential of efavirenz in primary human hepatocytes.
    Mugundu GM; Hariparsad N; Desai PB
    Drug Metab Lett; 2010 Jan; 4(1):45-50. PubMed ID: 20201776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment.
    Ngaimisi E; Minzi O; Mugusi S; Sasi P; Riedel KD; Suda A; Ueda N; Bakari M; Janabi M; Mugusi F; Bertilsson L; Burhenne J; Aklillu E; Diczfalusy U
    J Antimicrob Chemother; 2014 Dec; 69(12):3311-9. PubMed ID: 25096076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir].
    Bernal E; Masiá M; Padilla S; Ramos JM; Martín-Hidalgo A; Gutiérrez F
    Med Clin (Barc); 2007 Jul; 129(7):252-4. PubMed ID: 17683706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early or deferred initiation of efavirenz during rifampicin-based TB therapy has no significant effect on CYP3A induction in TB-HIV infected patients.
    Aklillu E; Zumla A; Habtewold A; Amogne W; Makonnen E; Yimer G; Burhenne J; Diczfalusy U
    Br J Pharmacol; 2021 Aug; 178(16):3294-3308. PubMed ID: 33155675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.
    Röshammar D; Simonsson US; Ekvall H; Flamholc L; Ormaasen V; Vesterbacka J; Wallmark E; Ashton M; Gisslén M
    J Pharmacokinet Pharmacodyn; 2011 Dec; 38(6):727-42. PubMed ID: 21964996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atazanavir: its role in HIV treatment.
    Wood R
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):785-96. PubMed ID: 19053892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
    Le Tiec C; Barrail A; Goujard C; Taburet AM
    Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions between etonogestrel-releasing contraceptive implant and 3 antiretroviral regimens.
    Kreitchmann R; Stek A; Best BM; Capparelli E; Wang J; Shapiro D; Chakhtoura N; Mirochnick M; Eke AC;
    Contraception; 2022 Jan; 105():67-74. PubMed ID: 34407424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of 4β-Hydroxycholesterol and 25-Hydroxycholesterol as Endogenous Biomarkers of CYP3A4: Study with CYP3A-Humanized Mice.
    Nitta SI; Hashimoto M; Kazuki Y; Takehara S; Suzuki H; Oshimura M; Akita H; Chiba K; Kobayashi K
    AAPS J; 2018 Apr; 20(3):61. PubMed ID: 29858698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing lopinavir and atazanavir plasma concentration.
    Stöhr W; Back D; Dunn D; Sabin C; Winston A; Gilson R; Pillay D; Hill T; Ainsworth J; Gazzard B; Leen C; Bansi L; Fisher M; Orkin C; Anderson J; Johnson M; Easterbrook P; Gibbons S; Khoo S;
    J Antimicrob Chemother; 2010 Jan; 65(1):129-37. PubMed ID: 19897506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.
    Busse KH; Formentini E; Alfaro RM; Kovacs JA; Penzak SR
    J Acquir Immune Defic Syndr; 2008 Aug; 48(5):561-6. PubMed ID: 18645517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric?
    Tomalik-Scharte D; Lütjohann D; Doroshyenko O; Frank D; Jetter A; Fuhr U
    Clin Pharmacol Ther; 2009 Aug; 86(2):147-53. PubMed ID: 19458613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy.
    Crane HM; Van Rompaey SE; Kitahata MM
    AIDS; 2006 Apr; 20(7):1019-26. PubMed ID: 16603854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.
    Cohen C; Nieto-Cisneros L; Zala C; Fessel WJ; Gonzalez-Garcia J; Gladysz A; McGovern R; Adler E; McLaren C;
    Curr Med Res Opin; 2005 Oct; 21(10):1683-92. PubMed ID: 16238909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Class-sparing regimens for initial treatment of HIV-1 infection.
    Riddler SA; Haubrich R; DiRienzo AG; Peeples L; Powderly WG; Klingman KL; Garren KW; George T; Rooney JF; Brizz B; Lalloo UG; Murphy RL; Swindells S; Havlir D; Mellors JW;
    N Engl J Med; 2008 May; 358(20):2095-106. PubMed ID: 18480202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients.
    Habtewold A; Amogne W; Makonnen E; Yimer G; Nylén H; Riedel KD; Aderaye G; Bertilsson L; Burhenne J; Diczfalusy U; Aklillu E
    Pharmacogenomics J; 2013 Dec; 13(6):484-9. PubMed ID: 23089673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atazanavir/ritonavir: a review of its use in HIV therapy.
    von Hentig N
    Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation.
    Hull MW; Harris M; Lima V; Guillemi S; Harrigan PR; Montaner JS
    J Clin Pharmacol; 2009 Feb; 49(2):155-61. PubMed ID: 19179294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys.
    Li K; Zhao S; Zhang L; Wu X; Shu P; Wang Y; Feng H; Gu Z; Han Hsu H
    Drug Metab Dispos; 2014 May; 42(5):839-43. PubMed ID: 24595680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.